Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(Suppl 11):S64–S85

17. Musci JO, Cornish JS, Dabritz J (2016) Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 51:531–547
18. Navarro-Compan V, Plasencia-Rodriguez C, De Miguel E et al (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford) 55:1188–1194
19. Plasencia C, Kneepkens EL, Wolbink G et al (2015) Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. J Rheumatol 42:1638–1646
20. Poddubnyy D, Gensler LS (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:807–818
21. Senabre-Gallego JM, Rosas-Gomez De Salazar J, Santos-Soler G et al (2011) Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease. Rheumatol Clin 7:385–388
22. Sieper J, Lenaerts J, Wollenhaupt J et al (2014) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73:108–113
23. Smolen JS, Braun J, Dougados M et al (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6–16
24. Van Der Heijde D, Landewe R, Feldtkeller E (2008) Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 67:489–493
25. Van Der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818
26. Zavada J, Uher M, Sisol K et al (2016) A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis 75:96–102

Z Rheumatol 2017 · 76:26
DOI 10.1007/s00393-016-0231-y
Online publiziert: 14. November 2016
© Springer-Verlag Berlin Heidelberg 2016

CrossMark

M. Schneider¹ · H. Carnarius² · T. Schlegl³

¹ Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland

² GlaxoSmithKline GmbH & Co KG, Hamburg, Deutschland

³ K&A BrandResearch, Nürnberg, Deutschland

Erratum zu: Partizipative Entscheidungsfindung auch bei komplexen systemischen Autoimmunerkrankungen wie dem systemischen Lupus erythematodes (SLE)?

Erratum zu:
Z Rheumatol
doi:10.1007/s00393-016-0208-x

Bitte beachten Sie die korrigierten Affiliationen der Autoren. Wir bitten den Fehler zu entschuldigen.

Korrespondenzadresse

Prof. Dr. M. Schneider
Poliklinik, Funktionsbereich und Hiller
Forschungszentrum für Rheumatologie,
Universitätsklinikum Düsseldorf
Moorenstr. 5, 40225 Düsseldorf, Deutschland
schneiderm@med.uni-duesseldorf.de

Die Online-Version des Originalbeitrages finden Sie unter <http://dx.doi.org/10.1007/s00393-016-0208-x>.